175 related articles for article (PubMed ID: 35558158)
1. Combination with Toll-like receptor 4 (TLR4) agonist reverses GITR agonism mediated M2 polarization of macrophage in Hepatocellular carcinoma.
Pan C; Wu Q; Wang S; Mei Z; Zhang L; Gao X; Qian J; Xu Z; Zhang K; Su R; Guo D; Zhou L; Zheng S
Oncoimmunology; 2022; 11(1):2073010. PubMed ID: 35558158
[TBL] [Abstract][Full Text] [Related]
2. Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation.
Cohen AD; Schaer DA; Liu C; Li Y; Hirschhorn-Cymmerman D; Kim SC; Diab A; Rizzuto G; Duan F; Perales MA; Merghoub T; Houghton AN; Wolchok JD
PLoS One; 2010 May; 5(5):e10436. PubMed ID: 20454651
[TBL] [Abstract][Full Text] [Related]
3. Characterization of MK-4166, a Clinical Agonistic Antibody That Targets Human GITR and Inhibits the Generation and Suppressive Effects of T Regulatory Cells.
Sukumar S; Wilson DC; Yu Y; Wong J; Naravula S; Ermakov G; Riener R; Bhagwat B; Necheva AS; Grein J; Churakova T; Mangadu R; Georgiev P; Manfra D; Pinheiro EM; Sriram V; Bailey WJ; Herzyk D; McClanahan TK; Willingham A; Beebe AM; Sadekova S
Cancer Res; 2017 Aug; 77(16):4378-4388. PubMed ID: 28611044
[TBL] [Abstract][Full Text] [Related]
4. Synergistic antitumor responses by combined GITR activation and sunitinib in metastatic renal cell carcinoma.
Yu N; Fu S; Xu Z; Liu Y; Hao J; Zhang A; Wang B
Int J Cancer; 2016 Jan; 138(2):451-62. PubMed ID: 26239999
[TBL] [Abstract][Full Text] [Related]
5. GITR ligation enhances functionality of tumor-infiltrating T cells in hepatocellular carcinoma.
van Beek AA; Zhou G; Doukas M; Boor PPC; Noordam L; Mancham S; Campos Carrascosa L; van der Heide-Mulder M; Polak WG; Ijzermans JNM; Pan Q; Heirman C; Mahne A; Bucktrout SL; Bruno MJ; Sprengers D; Kwekkeboom J
Int J Cancer; 2019 Aug; 145(4):1111-1124. PubMed ID: 30719701
[TBL] [Abstract][Full Text] [Related]
6. GITR Agonism Enhances Cellular Metabolism to Support CD8
Sabharwal SS; Rosen DB; Grein J; Tedesco D; Joyce-Shaikh B; Ueda R; Semana M; Bauer M; Bang K; Stevenson C; Cua DJ; Zúñiga LA
Cancer Immunol Res; 2018 Oct; 6(10):1199-1211. PubMed ID: 30154083
[TBL] [Abstract][Full Text] [Related]
7. Agonist anti-GITR antibody significantly enhances the therapeutic efficacy of Listeria monocytogenes-based immunotherapy.
Shrimali R; Ahmad S; Berrong Z; Okoev G; Matevosyan A; Razavi GSE; Petit R; Gupta S; Mkrtichyan M; Khleif SN
J Immunother Cancer; 2017 Aug; 5(1):64. PubMed ID: 28807056
[TBL] [Abstract][Full Text] [Related]
8. Mature B cells are critical to T-cell-mediated tumor immunity induced by an agonist anti-GITR monoclonal antibody.
Zhou P; Qiu J; L'Italien L; Gu D; Hodges D; Chao CC; Schebye XM
J Immunother; 2010 Oct; 33(8):789-97. PubMed ID: 20842058
[TBL] [Abstract][Full Text] [Related]
9. GITR Agonism Triggers Antitumor Immune Responses through IL21-Expressing Follicular Helper T Cells.
Koh CH; Kim IK; Shin KS; Jeon I; Song B; Lee JM; Bae EA; Seo H; Kang TS; Kim BS; Chung Y; Kang CY
Cancer Immunol Res; 2020 May; 8(5):698-709. PubMed ID: 32122993
[TBL] [Abstract][Full Text] [Related]
10. GITR agonist enhances vaccination responses in lung cancer.
Zhu LX; Davoodi M; Srivastava MK; Kachroo P; Lee JM; St John M; Harris-White M; Huang M; Strieter RM; Dubinett S; Sharma S
Oncoimmunology; 2015 Apr; 4(4):e992237. PubMed ID: 26137407
[TBL] [Abstract][Full Text] [Related]
11. Quantitative systems pharmacology model of GITR-mediated T cell dynamics in tumor microenvironment.
Ji Y; Madrasi K; Knee DA; Gruenbaum L; Apgar JF; Burke JM; Gomes B
CPT Pharmacometrics Syst Pharmacol; 2023 Mar; 12(3):413-424. PubMed ID: 36710369
[TBL] [Abstract][Full Text] [Related]
12. Depletion of regulatory T cells by anti-GITR mAb as a novel mechanism for cancer immunotherapy.
Coe D; Begom S; Addey C; White M; Dyson J; Chai JG
Cancer Immunol Immunother; 2010 Sep; 59(9):1367-77. PubMed ID: 20480365
[TBL] [Abstract][Full Text] [Related]
13. Glucocorticoid-induced tumor necrosis factor receptor-related protein co-stimulation facilitates tumor regression by inducing IL-9-producing helper T cells.
Kim IK; Kim BS; Koh CH; Seok JW; Park JS; Shin KS; Bae EA; Lee GE; Jeon H; Cho J; Jung Y; Han D; Kwon BS; Lee HY; Chung Y; Kang CY
Nat Med; 2015 Sep; 21(9):1010-7. PubMed ID: 26280119
[TBL] [Abstract][Full Text] [Related]
14. Anti-GITR Antibody Treatment Increases TCR Repertoire Diversity of Regulatory but not Effector T Cells Engaged in the Immune Response Against B16 Melanoma.
Scirka B; Szurek E; Pietrzak M; Rempala G; Kisielow P; Ignatowicz L; Miazek A
Arch Immunol Ther Exp (Warsz); 2017 Dec; 65(6):553-564. PubMed ID: 28638937
[TBL] [Abstract][Full Text] [Related]
15. Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs.
Lu L; Xu X; Zhang B; Zhang R; Ji H; Wang X
J Transl Med; 2014 Feb; 12():36. PubMed ID: 24502656
[TBL] [Abstract][Full Text] [Related]
16. Stimulation of the glucocorticoid-induced TNF receptor family-related receptor on CD8 T cells induces protective and high-avidity T cell responses to tumor-specific antigens.
Côté AL; Zhang P; O'Sullivan JA; Jacobs VL; Clemis CR; Sakaguchi S; Guevara-Patiño JA; Turk MJ
J Immunol; 2011 Jan; 186(1):275-83. PubMed ID: 21106849
[TBL] [Abstract][Full Text] [Related]
17. GITR pathway activation abrogates tumor immune suppression through loss of regulatory T cell lineage stability.
Schaer DA; Budhu S; Liu C; Bryson C; Malandro N; Cohen A; Zhong H; Yang X; Houghton AN; Merghoub T; Wolchok JD
Cancer Immunol Res; 2013 Nov; 1(5):320-31. PubMed ID: 24416730
[TBL] [Abstract][Full Text] [Related]
18. Anaphylaxis caused by repetitive doses of a GITR agonist monoclonal antibody in mice.
Murphy JT; Burey AP; Beebe AM; Gu D; Presta LG; Merghoub T; Wolchok JD
Blood; 2014 Apr; 123(14):2172-80. PubMed ID: 24558202
[TBL] [Abstract][Full Text] [Related]
19. GITR ligand fusion protein agonist enhances the tumor antigen-specific CD8 T-cell response and leads to long-lasting memory.
Durham NM; Holoweckyj N; MacGill RS; McGlinchey K; Leow CC; Robbins SH
J Immunother Cancer; 2017; 5():47. PubMed ID: 28649380
[TBL] [Abstract][Full Text] [Related]
20. Caveolin-mediated cytosolic delivery of spike nanoparticle enhances antitumor immunity of neoantigen vaccine for hepatocellular carcinoma.
Lin Z; Jiang C; Wang P; Chen Q; Wang B; Fu X; Liang Y; Zhang D; Zeng Y; Liu X
Theranostics; 2023; 13(12):4166-4181. PubMed ID: 37554274
[No Abstract] [Full Text] [Related]
[Next] [New Search]
